25,942 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Point72 Hong Kong Ltd

Point72 Hong Kong Ltd bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,942 shares of the company's stock, valued at approximately $22,983,000. Eli Lilly and Company accounts for about 1.6% of Point72 Hong Kong Ltd's investment portfolio, making the stock its 10th largest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. International Assets Investment Management LLC lifted its holdings in Eli Lilly and Company by 87,091.7% during the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock valued at $11,041,631,000 after purchasing an additional 12,448,888 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Eli Lilly and Company by 2.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,115,504 shares of the company's stock valued at $5,417,970,000 after purchasing an additional 157,741 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Fisher Asset Management LLC now owns 5,058,101 shares of the company's stock valued at $4,481,175,000 after purchasing an additional 169,391 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Eli Lilly and Company by 5.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock valued at $3,242,296,000 after buying an additional 171,595 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Eli Lilly and Company by 0.7% in the second quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company's stock worth $2,741,832,000 after buying an additional 22,392 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 0.9 %

NYSE LLY traded up $7.16 during trading on Friday, hitting $795.35. The stock had a trading volume of 2,206,918 shares, compared to its average volume of 4,869,603. The firm has a 50 day moving average price of $851.90 and a 200 day moving average price of $870.26. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $755.04 billion, a PE ratio of 85.98, a PEG ratio of 3.01 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm's revenue was up 20.4% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.65%. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price objective on the stock. Wells Fargo & Company raised their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an "overweight" rating in a report on Friday, August 9th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price target on the stock. Morgan Stanley restated an "overweight" rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a "hold" rating in a research report on Thursday, September 5th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.